Leah Cohen

Leah Cohen

Auto-generated profile, based on publicly available information

Leah Cohen

Department of Dermatology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2020 in Journal of the American Academy of Dermatology
Verified
Journal Article
Closed access
Nirav R. ShahNirav R. Shah
Nirav R. Shah
LCLeah Cohen
Leah Cohen
LVLucia Seminario Vidal
Lucia Seminario Vidal

1 January 2023 in Dermatologic Therapy
Verified
Journal Article
Open access
PDF file
DWDavid M. Weiner
David M. Weiner
SRSupriya Rastogi
Supriya Rastogi
LCLeah Cohen
Leah Cohen
SCSara Choi
Sara Choi
CVCarmela C. Vittorio
Carmela C. Vittorio
SBStefan K Barta
Stefan K Barta
Mogamulizumab is a novel monoclonal antibody designed to target CC chemokine receptor 4 (CCR4), which is expressed by tumor cells in cutaneous T‐cell lymphoma (CTCL). In clinical trials, mogamulizumab monotherapy has demonstrated efficacy in reducing tumor burden in advanced CTCL, particularly in the peripheral blood. In clinical practice at our center, mogamulizumab has been combined with other agents such as systemic interferon, systemic retinoids, and extracorporeal photopheresis for an enhanced synergistic effect. There is limited published research on mogamulizumab combination therapy. This study evaluates the clinical efficacy of mogamulizumab in combination with systemic interferon, retinoids, and/or extracorporeal photopheresis for therapy of CTCL. Nineteen patients on this regimen at our academic center were identified. Treatment response rates, progression‐free survival, duration of response, and adverse effects were characterized by retrospective chart review. All patients on this regimen at our center had an initial partial or complete response. Moreover, responses were durable, and the regimen was well‐tolerated with few grade 3 adverse effects. These results demonstrate the utility of a multimodality approach to the therapy of CTCL with mogamulizumab and warrant further confirmation.

22 May 2019 in Molecular Carcinogenesis
Verified
Journal Article
Open access
PDF file
LCLeah Cohen
Leah Cohen
KTKenneth Y. Tsai
Kenneth Y. Tsai
Merkel cell carcinoma (MCC) is a rare neuroendocrine carcinoma of the skin, for which the exact mechanisms of carcinogenesis remain unknown. Therapeutic options for this highly aggressive malignancy have historically been limited in both their initial response and response durability. Recent improvements in our understanding of MCC tumor biology have expanded therapeutic options for these patients, namely through the use of immunotherapies such as immune checkpoint inhibitors. Further elucidation of the tumor mutational landscape has identified molecular targets for therapies, which have demonstrated success in other cancer types. In this review, we discuss both current and investigational immune and molecular targets of therapy for MCC.

22 March 2020 in Lupus
Verified
Journal Article
Closed access
PDF file
LCLeah Cohen
Leah Cohen
VSVidhi Shah
Vidhi Shah
PCPei-Ling Chen
Pei-Ling Chen
JMJane Messina
Jane Messina
LSLucia Seminario-Vidal
Lucia Seminario-Vidal
Hypertrophic lupus erythematosus is a variant of discoid lupus erythematosus, which manifests as verrucous plaques and/or keratoacanthoma-like nodules on the face and arms. Diagnosis and treatment of hypertrophic lupus erythematosus can be challenging as it can resemble cutaneous squamous cell carcinoma clinically and histopathologically. Furthermore, cutaneous squamous cell carcinoma is a known complication of discoid lupus erythematosus. We present a diagnostically challenging case of a patient with a rapidly enlarging rhinophymatous mass and multiple keratoacanthoma-like lesions of the bilateral upper extremities whose work-up was initially equivocal. CD123 staining helped to elucidate a final diagnosis of cutaneous squamous cell carcinoma arising in a background of occult hypertrophic lupus erythematosus.

7 April 2019 in Case Reports in Dermatological Medicine
Verified
Journal Article
Open access
PDF file
LCLeah Cohen
Leah Cohen
SNSonali Nanda
Sonali Nanda
MZMartin Zaiac
Martin Zaiac
Objectives. To present a case of desmoplastic melanoma (DM) arising after laser therapy of a suspected solar lentigo with the 1,064 nm Q-switched (QS) Neodymium:Yttrium-Aluminum-Garnet (Nd:YAG) laser and discuss the safety of treating suspected solar lentigines with laser therapy.Methods. Case presentation with discussion.Results. We describe a patient who developed DM after 1,064 nm QS Nd:YAG laser therapy to a suspected solar lentigo.Conclusions. Limited generalizable studies regarding the safety of laser therapy for solar lentigines exist, specifically for the 1,064 nm QS Nd:YAG laser. Therefore, we recommend caution is taken when considering laser therapy for these lesions, as well as strong consideration for histologic confirmation prior to therapy.